Emerging Insights on Adverse Events During ART and Implications for Treatment: Nephrotoxicity and Long-Acting Injectables

In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.

Presenters:

Fidelia Bernice, PharmD
Clinical Pharmacy Specialist
Infectious Diseases
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland

Aadia I. Rana, MD
Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama

Content based on a CME program supported by independent educational grants fromJanssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.

Link to full program:
https://bit.ly/3ydMtcL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.